Other than the aforementioned FDA approved agents, an anilide type HDAC inhibitor, chidamide (8), has also been approved by CFDA to treat patients with R/R PTCL [72]. The gene discussed is HDAC9; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.